WuXi AppTec: Home

WuXi AppTec

Integrated End-to-End CRDMO Platform

Our Vision

Every Drug Can Be Made and Every Disease Can Be Treated

By Building an Open-access Platform with the Most Comprehensive Capabilities and Technologies in the Global Healthcare Industry

Our Values

Integrity & Dedication, Working Together & Sharing Success; Doing the Right Thing, Doing It Right.

About us

Enabling Innovation

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and

SEE MORE

Foster Collaboration with Innovative Solutions

An Integrated CRDMO Business Model

Supporting our customers to deliver groundbreaking treatments to patients around the world

Research

Development

Manufacturing

Research

Our Company

Empowering Health Innovation

Collaborating with partners to deliver comprehensive capabilities and innovative technologies in the pharmaceutical and healthcare industry

WuXi Chemistry

WuXi Chemistry

Provides CRDMO services for new drug development from discovery to commercial SEE MORE > WuXi Biology

WuXi Biology

A full spectrum of biology services and solutions supporting stand-alone and integrated projectsSEE MORE > WuXi Testing

WuXi Testing

Seamless drug and medical device testing services from preclinical testing to clinical trialsSEE MORE > WuXi Advanced Therapies

WuXi Advanced Therapies

Global CTDMO offering an integrated end-to-end solution to accelerate time to market for cell and gene therapiesSEE MORE >

News

The Latest News about WuXi AppTec

WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating

WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year

WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating

Shanghai, November 20, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been awarded a gold medal in the 2024 EcoVadis business sustainability rating, ranking in the top 2% of all participating companies. This achievement reflects WuXi AppTec’s commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the company’s business strategies and operations.

Read more

WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

Couvet, Switzerland - November 14, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, is proud to announce that its facility in Couvet, Switzerland, has received a silver medal in the 2024 business sustainability ratings by EcoVadis, a leading business sustainability rating provider. This recognition highlights WuXi AppTec’s steadfast commitment to integrating Environmental, Social, and Governance (ESG) priorities into its strategy and operations.

Read more

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

Shanghai, November 11, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Global Corporate Sustainability Assessment (CSA), as of November 11, 2024.

Read more

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

SHANGHAI, October 29, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a growth advisory firm. This marks the eighth consecutive year that WuXi AppTec has achieved this distinction.

Read more

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

(SHANGHAI, October 28, 2024) — WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the first three quarters ending September 30, 2024 (“Reporting Period”)

Read more

WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year

Shanghai, September 1, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced that it has maintained its AA MSCI (Morgan Stanley Capital International) ESG rating for the fourth consecutive year. The rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into the company’s business strategies and operations.

Read more

Careers

Welcome to Our Team

Become Part of Creating a Better Life

Join Us

Investors

The Latest Financial Reports, Announcements and Resources

SEE MORE